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RECURRENT APHTHOUS STOMATITIS – A REVIEW
AISHWARYA J, BRUNDHA MP*
Aphthous stomatitis is a most common condition which affects the oral cavity and it is painful. Aphthous ulcer is characterized by the repeated 
occurrence of benign and non-contagious mouth ulcers. It can be caused due to triggering of T-cell-mediated immune response, by various factors. 
This condition is very common, affecting about 15–20% of the population. The lesions generally occur on the cheeks, lips, gums, floor, and roof of the 
mouth. There are three different types of aphthous stomatitis they are aphthous ulcer major, aphthous ulcer minor, and herpetiform ulcers. It can be 
also termed as recurrent aphthous ulcer, recurring oral aphthae, and recurrent aphthous ulceration. Informal term is canker sores.
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INTRODUCTION
Recurrent aphthous stomatitis (RAS) is spontaneously occurring 
self-limiting ulceration in the oral cavity. It can be single or multiple 
lesions present in the non-keratinized parts of the oral mucosa [1]. It 
is characterized by painful necrotizing ulcers whose etiology is not 
clearly understood [2]. The lesions are shallow and covered by grayish-
white pseudomembrane with an erythematous margin [3]. It is often 
associated with redness, swelling, and occasional bleeding from the 
affected areas [4]. These lesions differ from the ulceration produced by 
the herpes simplex virus [5]. The RAS often causes pain during eating, 
sleeping, and speaking [6]. In HIV patients, these ulcers are more 
frequently progressive, destructive, and debilitating [7].
INCIDENCE
Recurrent aphthous ulcer occurs in children as well as in adults. It 
is common and affects almost 20% of the population [8,9], mostly 
people belonging to higher socioeconomic status [10,11]. It occurs 
in adolescence and frequency of the disease decreases with age. 
Females are more prone to RAS than males and children [12-15]. If the 
ulcers occur before 5 years of age or after 30 years, then it should be 
considered as more complex disorder [16-19].
Aphthous ulcer minor (MiAU)
This is the most common form, accounting for 80% of all cases. Oral 
mucosal ulcers which are discrete and <1 cm in diameter characterize 
this form of aphthous ulcer. MiAU infrequently presents as a small 
single ulcer. Lesions heal without scarring within 7–10 days. The 
periodicity varies between individuals, with some having longer 
ulcer-free episodes and some never being free from ulcers [1]. MiAU; 
Mikulicz ulcer occur mainly in the 10–40-year-old age group, often 
cause minimal symptoms. The ulcer floor is initially yellowish in color 
but assumes a grayish hue as healing and epithelialization proceeds. 
They are surrounded by an erythematous halo and some edema and are 
found mainly on the non-keratinized mobile mucosa of the lips, cheeks, 
floor of the mouth, and sulci or ventrum of the tongue. They are only 
uncommonly seen on the keratinized.
Mucosa of the palate or dorsum of the tongue and occur in groups of 
only a few ulcers (1–6) at a time [21].
Aphthous ulcer major (MaAU)
This is formerly known as periadenitis mucosa necrotica recurrens 
(PMNR). This form is less common than the others and is characterized 
by oval ulcers >1 cm in diameter. Occasionally, MaAU is a relatively 
severe form; many major aphthae may be present simultaneously. 
Ulcers are large and deep, may have irregular borders, and may coalesce. 
On healing, which may take as long as 6 weeks, ulcers can leave scarring 
and severe distortion of oral and pharyngeal mucosa may occur [1]. 
MjAU; Sutton’s ulcers; PMNR are larger, of longer duration, of more 
frequent recurrence, and often more painful than minor ulcers. MjAUs 
are round or ovoid-like minor ulcers, but they are larger and associated 
with surrounding edema and can reach a large size, usually about 
1 cm in diameter or even larger. They are found on any area of the oral 
mucosa, including the keratinized dorsum of the tongue or palate, occur 
in groups of only a few ulcers (1–6) at one time and heal slowly over 
10–40 days. They recur extremely frequently may heal with scarring 
and are occasionally found with a raised erythrocyte sedimentation 
rate or plasma viscosity [21].
Herpetiform recurrent aphthous ulcer
This least common form (5–10% of cases) has the smallest of the 
aphthous ulcers, commonly <1 mm in diameter in size. The ulcers tend 
to occur in clusters that may consist of tens or hundreds of minute 
ulcers. Clusters may be small and localized, or they may be distributed 
throughout the soft mucosa of the oral cavity [24]. Herpetiform 
ulceration is found in a slightly older age group than the other forms of 
RAS and is found mainly in females. They begin with vesiculation which 
passes rapidly into multiple minute pinhead-sized discrete ulcers, 
which involve any oral site including the keratinized mucosa. They 
usually increase in size and coalesce to leave large round ragged ulcers, 
which heal in 10 days or longer, are often extremely painful and recur so 
frequently that ulceration may be virtually continuous [21].
ETIOLOGY
The etiology of RAS is still not understood, although many predisposing 
and precipitating factors have been described, namely, trauma, stress, 
changes in the immune system, sensitivity to certain types of food or 
ingested substances such as preservative agents or substances such as 
cinnamaldehyde or sodium lauryl sulfate present in some toothpaste, 
and iron, zinc, and vitamin deficiency [26,27]. Alteration of local cell-
mediated immunity is often encountered in patients with RAU. Systemic 
T- and B-cell responses have also been reported as altered in patients 
with RAU [28]. Histologically, aphthous ulcers contain a mononuclear 
infiltrate with a fibrin coating [29]. RAS may be also one of the symptoms 
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of the Behçet’s syndrome – a systemic, inflammatory disease, where, apart 
from oral and genital lesions, various general symptoms may occur. They 
include anterior or posterior uveitis, retinal vasculitis, erythema nodosum, 
cutaneous vasculitis and arthralgia, and less commonly – dysfunction of 
the gastrointestinal tract, nervous system, and kidneys [30-34].
Hypersensitivity reactions to exogenous antigens other than gluten do 
not have a significant etiological role in RAS [35]. Infectious agents such 
as Helicobacter pylori and herpes simplex virus have been investigated 
but have not been consistently found in aphthous ulcers [36]. It can 
also be due to immunological attack as in lichen planus, pemphigoid, or 
pemphigus; damage because of an immune defect as in HIV disease and 
leukemia; infections such as herpes viruses, tuberculosis, and syphilis; 
cancer and nutritional defects such as vitamin deficiencies and some 
gastrointestinal diseases [21]. There is a genetic basis behind RAS, 
more than 42% of patients have first-degree relatives with RAS [37]. 
The occurrence is 90% if both the parents are affected, but only 20% if 
anyone of them are only affected. It is likely to be more severe and starts 
at an early age in patients with family history than the ones without [38]. 
There are few patients whose RAS remits with oral contraceptives or 
during pregnancy [39]. A minority of women with RAS have cyclical oral 
ulceration related to the luteal phase of the menstrual cycle [40-43]. 
A link with autoimmune progesterone dermatitis is most unlikely [44]. 
Several reports document the negative association between smoking 
and the occurrence of RAU [6].
TREATMENT
Treatment for RAS is symptomatic; the goals being to decrease pain, 
healing time, number and size of the ulcer, and to increase disease-free 
periods because the main etiology is not clearly understood. Current 
treatment options include topical agents, systemic and topical steroids, 
corticosteroids, cauterization, antibiotics, mouthrinses containing 
active enzymes, laser treatments, and combination therapy [45].
Topical treatment
Amlexanox is a topical preparation that is effective in the treatment of 
RAS. The drug was approved by the US Food and Drug Administration 
in 1996 as the first treatment for aphthous ulcers in immunocompetent 
patients. Amlexanox is an anti-inflammatory that inhibits leukotrienes 
and histamines, although its exact mechanism of action in the treatment 
of RAS is unknown [46]. Specifically, application of amlexanox as a 5% 
paste to ulcerations resulted in complete resolution of pain 1.3 days 
sooner than no treatment and 0.7 days sooner than vehicle alone. 
Similarly, amlexanox reduced complete healing by 1.6 days compared 
with no treatment and by 0.7 days compared with vehicle alone. 
Ointments, unlike gels or creams, do not burn or sting when applied 
to ulcerations, although they adhere poorly to mucosa. Elixir forms of 
corticosteroids such as dexamethasone can be used as an oral rinse for 
patients with multiple ulcerations [5].
Other antimicrobial compounds including the mouthwash Listerine® 
(Warner–Lambert Consumer Healthcare, Morris Plains, NJ), whose 
active ingredients include a mixture of essential oils, can be used to 
decrease the duration and severity of RAS and to possibly reduce the 
occurrence of ulcerations in susceptible patients [47].
Chlorhexidine gluconate, a widely prescribed oral rinse used to reduce 
plaque and gingivitis, increases ulcer healing and intervals between 
episodes of RAS but not the recurrence rate of oral ulcerations [48].
The commonly used agents are betamethasone, fluocinonide, 
fluocinolone, fluticasone, and clobetasol. These agents are found to be 
more effective than hydrocortisone and triamcinolone, but higher risk 
for adrenocortical suppression and predisposition to candidiasis. So in 
clinical practice, triamcinolone or fluocinonide dental paste is used as 
topical application over the ulcers 2–3 times daily for 5 days [6].
containing toothpaste is not beneficial [50]. Carbenoxolone sodium 
mouthwash reduced the severity of RAS in one study [51].
Pain relief may be achieved with 2% viscous lidocaine applied with a 
cotton swab several times daily, as needed [24,52]. Over-the-counter 
benzocaine preparations (e.g., Anbesol and Oragel) may also be used. 
Fig. 1:  [20]
Fig. 2: [22]
Fig. 3:  [23]
Sodium  cromoglycate  lozenges  may  provide  mild 
symptomatic relief (Dolby and Walker, 1975; Kowolik et al., 1978), [49] 
but cromoglycate-
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Over-the-counter agents such as orabase or zilactin-B coat aphthous 
ulcers and provide local protection [52].
Topical tetracyclines (e.g., aureomycin, chlortetracycline, and 
tetracycline) may reduce healing times and/or reduce the associated 
pain of RAS [53-57], but they may cause dysgeusia, oral candidosis, 
and a burning-like sensation of the pharynx, and they are not suitable 
for young children who might ingest them, with resultant tooth 
staining [58].
Topical immunomodulatory agents that have been suggested to be 
of some benefit in the management of RAS include azelastine [59], 
human alpha-2-interferon in cream [60,61], topical cyclosporine [62], 
deglycyrrhizinated licorice [63], topical 5-aminosalicylic acid [64], and 
prostaglandin E2 gel [65].
Other topical treatments such as sucralfate have also been proposed, 
which act by forming a protective film on the bottom of the oral ulcers, 
reducing pain, and shortening healing time [66].
Systemic treatment
The use of systemic agents should be reserved for patients with frequent 
episodes of painful and multiple ulcerations. An exception is the use of 
systemic corticosteroids as an acute treatment for patients [5].
Pentoxifylline is an anti-inflammatory, immunomodulatory, 
methylxanthine derivative that blocks neutrophil adherence and is 
indicated for RAS. The mode of action for pentoxifylline appears to be 
due to the inhibition of tumor necrosis factor and other inflammatory 
cytokines [67,68]. Pentoxifylline, 400 mg 3 times daily, have reported 
excellent results, some with long-term benefits [69,70].
Colchicine therapy is indicated in the prevention of RAS [71,72]. Doses 
of 0.6 mg, administered 3 times daily, appear to not only decrease the 
severity of RAS but also increase the intervals between episodes. At 
least 50% of patients appear to respond to treatment, and responders 
may be maintained on therapy chronically. Colchicine can cause 
gastrointestinal side effects, especially diarrhea, which may limit its 
use. Some patients can tolerate only 1 or 2 doses daily, which may 
limit its use as suppressive therapy. Colchicine-induced myopathy and 
neuropathy require monitoring for patients on long-term therapy. Bone 
marrow depression also has been reported, primarily in cases of acute 
colchicine intoxication [73].
Prednisone, at doses of 40–60 mg administered daily for 3–4 days, 
usually relieves inflammation and pain. Severe ulcerations may require 
2 full weeks of treatment with tapering doses with ulcerations [5].
The use of dapsone in the management of RAS is especially valuable for 
patients who require suppressive therapy. Like colchicine, dapsone may 
exert its effects primarily through suppression of inflammatory cell 
migration. Daily doses of 50–150 mg may be used chronically to suppress 
ulcer formation. Dapsone should not be administered to patients with a 
glucose-6-phosphate dehydrogenase deficiency and careful monitoring 
for hemolytic anemia is also essential. A hypersensitivity to dapsone 
characterized by fever, hepatitis, cholestatic jaundice, and rash is 
rare [74]; and agranulocytosis, another uncommon complication of 
dapsone, typically develops 8–12 weeks after initiation of therapy.
Thalidomide has proven to be effective at doses of 100–200 mg/day 
for treating RAS in patients infected with HIV and has become the drug 
of choice for patients with severe disease [7,75]. Less severe adverse 
effects, including sedation, headache, weight gain, nausea, constipation, 
and rash, are reversible when the drug is discontinued. Patients started 
on thalidomide therapy may require 2–3 months of treatment before a 
response is observed. A daily dose of 100–150 mg will usually suppress 
ulcer formation, although some patients may require higher doses. 
Once controlled, the dose may be tapered to alternate-day or every 3rd-
day therapy [5].
Levamisole rarely causes objective clinical improvement [76], and 
the associated adverse effects (nausea, hyperosmia, dysgeusia, and 
agranulocytosis) discourage its use [77-83].
Transfer factor [84] and gammaglobulin therapy [85] have been 
suggested to be beneficial, but more detailed studies are needed to 
confirm these preliminary observations.
The reported clinical benefit of monoamine oxidase inhibitor therapy 
in the treatment of three patients with RAS [86,87] was probably due 
to accompanying dietary modifications rather than any alteration in 
psychological status.
CONCLISION
Recurrent aphthous ulcer is the most common ulcer of the oral cavity, 
whose etiology is not well known. However, there are many treatments 
available for the prevention as well as for the cure of ulcers.
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